GlaxoSmithKline (LON:GSK) Rating Reiterated by Barclays

GlaxoSmithKline (LON:GSKGet Rating)‘s stock had its “equal weight” rating reaffirmed by stock analysts at Barclays in a research report issued on Friday, Marketbeat Ratings reports. They currently have a GBX 1,800 ($22.49) price objective on the stock. Barclays‘s target price suggests a potential upside of 1.42% from the stock’s current price.

A number of other research analysts also recently weighed in on GSK. Jefferies Financial Group set a GBX 2,100 ($26.23) target price on shares of GlaxoSmithKline in a research report on Wednesday, April 27th. Citigroup reissued a “neutral” rating and set a GBX 1,600 ($19.99) price objective on shares of GlaxoSmithKline in a report on Tuesday, January 18th. The Goldman Sachs Group set a GBX 2,000 ($24.98) target price on GlaxoSmithKline in a research note on Friday, January 7th. JPMorgan Chase & Co. set a GBX 1,740 ($21.74) price target on GlaxoSmithKline in a research note on Monday, April 25th. Finally, Credit Suisse Group set a GBX 1,400 ($17.49) price objective on GlaxoSmithKline in a research note on Thursday, April 28th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, GlaxoSmithKline has an average rating of “Hold” and a consensus target price of GBX 1,706.79 ($21.32).

GSK opened at GBX 1,774.80 ($22.17) on Friday. GlaxoSmithKline has a fifty-two week low of GBX 1,319.60 ($16.48) and a fifty-two week high of GBX 1,817 ($22.70). The firm has a 50-day moving average of GBX 1,655.49 and a 200 day moving average of GBX 1,603.24. The company has a debt-to-equity ratio of 113.27, a quick ratio of 0.53 and a current ratio of 0.79. The firm has a market cap of £90.23 billion and a P/E ratio of 20.75.

In other GlaxoSmithKline news, insider Charles Bancroft purchased 2,790 shares of the stock in a transaction on Wednesday, March 23rd. The shares were purchased at an average price of GBX 2,114 ($26.41) per share, with a total value of £58,980.60 ($73,679.70). Also, insider Emma Walmsley sold 34,031 shares of GlaxoSmithKline stock in a transaction dated Monday, February 14th. The shares were sold at an average price of GBX 1,610 ($20.11), for a total value of £547,899.10 ($684,446.10).

GlaxoSmithKline Company Profile (Get Rating)

GlaxoSmithKline plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare.

Featured Articles

Analyst Recommendations for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.